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A B S T R A C T
Experimental and prospective epidemiologic evidence suggest that arsenic exposure has diabetogenic effects.
However, little is known about how family exposure to arsenic may affect risk for type 2 diabetes (T2D)-related
outcomes in adulthood. We evaluated the association of both maternal and offspring arsenic exposure with
fasting glucose and incident T2D in 466 participants of the Strong Heart Family Study. Total arsenic (ΣAs)
exposure was calculated as the sum of inorganic arsenic (iAs) and methylated (MMA, DMA) arsenic species in
maternal and offspring baseline urine. Median maternal ΣAs at baseline (1989–91) was 7.6 µg/g creatinine,
while median offspring ΣAs at baseline (2001–03) was 4.5 µg/g creatinine. Median offspring glucose in
2006–2009 was 94 mg/dL, and 79 participants developed T2D. The fully adjusted mean difference (95% CI) for
offspring glucose was 4.40 (−3.46, 12.26) mg/dL per IQR increase in maternal ΣAs vs. 2.72 (−4.91 to 10.34)
mg/dL per IQR increase in offspring ΣAs. The fully adjusted odds ratio (95%CI) of incident T2D was 1.35 (1.07,
1.69) for an IQR increase in maternal ΣAs and 1.15 (0.92, 1.43) for offspring ΣAs. The association of maternal
ΣAs with T2D outcomes were attenuated with adjustment for offspring adiposity markers. Familial exposure to
arsenic, as measured in mothers 15–20 years before offspring follow-up, is associated with increased odds of
offspring T2D. More research is needed to confirm findings and better understand the importance of family
exposure to arsenic in adult-onset diabetes.
1. Introduction
Exposure to inorganic arsenic (iAs) is a major public health concern
in the US and globally. iAs is a recognized toxicant and carcinogen
common in groundwater and some foods (NTP, 2016; IARC, 2002).
Studies in Taiwan, Bangladesh and Mexico have found evidence to
support an association between moderate to high water arsenic levels
(≥50 µg/L) and type 2 diabetes (T2D) (Maull et al., 2012; Del Razo
et al., 2011). More recently, exposure to low-moderate and low water
arsenic levels (< 50 µg/L) has been associated with increased risk for,
and poor control of, T2D in the United States (Grau-Perez et al., 2017),
Denmark (Brauner et al., 2014), and Mexico (Coronado-González and
Del Razo, 2007).
The concept of the Developmental Origins of Health and Disease
(DOHaD) purports that early-life influences may induce long-term
metabolic changes and increase T2D risk in adulthood (Wadhwa et al.,
2009). Studies have shown that arsenic exposure likely induces epige-
netic modifications, typically in the form of DNA methylation that can
affect gene expression. This differential gene expression can be passed
down from mother to child, thus potentially influencing offspring
https://doi.org/10.1016/j.envint.2020.105531
Received 24 July 2019; Received in revised form 19 January 2020; Accepted 25 January 2020
⁎ Corresponding authors at: Columbia University Mailman School of Public Health, 722 W. 168th Street, Room 1105, New York, NY 10032, USA.
E-mail addresses: net2127@cumc.columbia.edu (N.E. Tinkelman), an2737@cumc.columbia.edu (A. Navas-Acien).
Environment International 137 (2020) 105531
0160-4120/ © 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by REPISALUD
health later in life (Smeester et al., 2014). The hypothesis that epige-
netic modifications influence disease risk later in life provides part of
the foundation for the DOHaD concept (Wadhwa et al., 2009).
Epidemiologic and experimental studies have demonstrated that
arsenic readily passes through the placenta and can cause develop-
mental toxicity (Hall et al., 2007; Concha et al., 1998). Prenatal arsenic
exposure has been associated with adverse birth outcomes, including
low birthweight (Hopenhayn et al., 2003; Yang et al., 2003; Rahman
et al., 2009; Huyck et al., 2007; Claus Henn et al., 2016; Guan et al.,
2012; Laine et al., 2015; Fei et al., 2013), a risk factor for T2D (Mi et al.,
2017 Dec). Prenatal and early-life arsenic exposure have also been as-
sociated with various adverse health outcomes later in life, including
increased risk for lung disease, cancer, and cardiovascular disease
(Naujokas et al., 2013). No epidemiologic research has been done,
however, on the effects of family exposure to arsenic on adult T2D-
related outcomes.
In this study, we evaluated the association of maternal arsenic ex-
posure with adult offspring fasting plasma glucose and insulin re-
sistance among American Indian communities in the Strong Heart Study
(SHS) and Strong Heart Family Study (SHFS). The SHS recruited adult
men and women from tribal communities in Arizona, Oklahoma and
North and South Dakota who were 45–74 years of age. The SHFS re-
cruited relatives of SHS members who were 14 years and older.
Historical data support that urine arsenic concentrations determined in
samples from 1989 to 1991, the baseline visit of the SHS, were constant
over a 10-year period (Navas-Acien et al., 2009). Based on water ar-
senic data, we also anticipate that urine arsenic measured at baseline
for mothers can reflect decades of prior exposure, including the preg-
nancy period and early years of life of the offspring (Wadhwa et al.,
2009). The family connections between the SHS and the SHFS allow us
to link maternal exposures, as determined in the SHS, with offspring
outcomes determined in the SHFS, providing a unique opportunity to
evaluate the role of maternal arsenic exposure in the current burden of
T2D affecting many tribal and rural communities in the United States
and globally. We hypothesized that higher urine arsenic levels in mo-
thers would be associated with increased fasting plasma glucose levels
and increased insulin resistance in their adult children.
2. Research design and methods
2.1. Study population
The SHS is a population-based prospective cohort study of tribal
members from American Indian communities in Arizona, Oklahoma
and North and South Dakota. The cohort consists of 4549 participants
ages 45–74 at baseline from 13 tribes who were recruited and examined
in 1989–1991. The SHFS is an extension of the SHS, in which family
members of SHS participants who had at least 5 living siblings in-
cluding 3 original SHS participants were invited to participate. This
cohort consists of 3838 participants from 96 families who were re-
cruited and examined in 1998–1999 and 2001–2003. Participants re-
cruited in 1998–1999 had follow-up visits in 2001–2003 and
2006–2009, while participants recruited in 2001–2003 had one follow-
up visit in 2006–2009. Maternal arsenic values were based on SHS visit
1 (1989–1991), and offspring arsenic values were based on the baseline
SHFS visit (1998–1999 or 2001–2003). Fasting glucose and homeostasis
model assessment for insulin resistance (HOMA2-IR) values were ob-
tained from the follow-up SHFS visit (2006–2009). Due to the constant
arsenic exposure over decades in these populations, the maternal ar-
senic values may reflect in utero exposure. Details about the methods
and design of the two studies have been previously published (Navas-
Acien et al., 2009; Lee et al., 1990; Scheer et al., 2012). Protocols were
approved by the Indian Health Service, institutional review boards, and
participating communities. All participants provided informed consent.
Pedigree information was used to link SHFS participants with at
least one parent in the SHS. Due to tribal request, data from one tribe
was not used (n = 1033 in SHS, n = 919 in SHFS). Offspring ages
14–93 (median 36) who had mothers in the SHS were selected for this
study (n = 1886). We excluded those with missing offspring ΣAs
(n = 476) and maternal ΣAs (n = 896) measurements, as well as off-
spring missing visit 5 (2006–2009) fasting glucose (n = 12) and
HOMA2-IR (n = 1). We further excluded those missing other covariates
(n = 35), including offspring and maternal eGFR, BMI, and waist cir-
cumference, and maternal fasting glucose. Finally, we excluded those
with incident diabetes at visit 5 (n = 79) from analyses with HOMA2-
IR. After all exclusions, a total of 466 participants were used in fasting
glucose analyses, and 387 participants were used in HOMA2-IR ana-
lyses presented here (Supplemental Fig. 1). Participants who were ex-
cluded did not differ appreciably from those who were included in the
analysis (Supplemental Table 2).
2.2. Urine arsenic measurements
Spot urine samples were collected in polypropylene tubes, frozen
within 1–2 h of collection, shipped in dry ice, and stored at −70 °C in
the Penn Medical Laboratory, MedStar Research Institute, Washington,
DC, USA (Lee et al., 1990). The freezers were operating under a strict
quality control system to guarantee secure sample storage. For arsenic
analyses, urine samples were thawed, and up to 1.0 mL was transferred
to a small vial, transported on dry ice to the Trace Element Laboratory,
Graz University, Austria, and stored at<− 70 °C until analysis.
Quality control and quality assurance methods have been described
previously (Scheer et al., 2012).
We measured urine arsenic species concentrations of arsenite, ar-
senate, methylarsonate (MMA), and dimethylarsinate (DMA) using high
performance liquid chromatography/inductively coupled plasma mass
spectrometry (HPLC/ICPMS). Urine arsenobetaine was measured using
HPLC/ICPMS together with other more rare arsenic cations. The con-
centrations measured for mother and offspring arsenobetaine were low
(median (IQR): 0.75 (0.50–1.50) µg/L for mothers and 0.55 (0.34–1.25)
µg/L for offspring), confirming that seafood consumption in this po-
pulation is infrequent. We used the sum of inorganic and methylated
(MMA and DMA) arsenic species as the biomarker of inorganic arsenic
exposure.
The inter-assay coefficients of variation, evaluated by including the
same reference urine sample in each batch of samples, were better than
5% for all species (Scheer et al., 2012). The limits of detection (LOD) for
arsenite, arsenate, MMA, DMA, and urine arsenobetaine were 0.1 µg/L.
Of the 466 participants used for the analyses, 19 (4.1%), 14 (3.0%), and
1 (0.21%) had offspring arsenobetaine, iAs, and MMA values below the
LOD, respectively. Six (1.3%) and 19 (4.1%) participants had maternal
arsenobetaine and iAs values below the LOD, respectively. No partici-
pants had offspring DMA, or maternal MMA or DMA below the LOD.
For participants with concentrations below the LOD, we imputed the
corresponding limit of detection divided by the square root of two.
2.3. Fasting glucose and insulin resistance
Fasting plasma samples were collected from all participants at each
examination after a 12-h fast and stored at<−70 °C (Howard et al.,
1992). Glucose was determined by enzymatic methods using reagent
kits from Boehringer Mannheim Diagnostic (Indianapolis, IN) on a
chemistry analyzer (Lee et al., 1990). Insulin was measured using
overnight radioimmunoassay. HOMA2-IR values were calculated with
the computed solved model for HOMA2-IR using fasting glucose and
insulin values (Levy et al., 1998). HOMA2-IR measurements at follow-
up were excluded for participants with T2D because HOMA2-IR cor-
relates well with insulin sensitivity in populations without T2D but not
among those with T2D (Resnick et al., 2002). Fasting glucose was
measured in all participants. Both variables were assayed at MedStar
Research Institute, Washington, DC (North et al., 2003).
T2D status was also assessed at visit 5 of the SHFS, defined as fasting
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plasma glucose ≥126 mg/dL, self-reported physician diagnosis or self-
reported use of insulin or oral diabetes treatment (Grau-Perez et al.,
2017). Of those included in this study, 79 had been diagnosed with T2D
at visit 5, 103 had impaired fasting glucose levels (100 ≤ fasting
plasma glucose< 126 mg/dL), and 284 had normal fasting glucose
levels. Due to the small number of participants with T2D, we lacked
power to directly assess diabetes as the outcome. Instead, we chose to
use continuous fasting glucose and HOMA2-IR as outcomes for this
study.
2.4. Other variables
Baseline information on sociodemographic data (age, sex, study
region), smoking history (never, former and current smoking), and
body mass index (kg/m2) were obtained during the SHS and SHFS
questionnaires and physical exams collected and performed by trained
and certified personnel using standardized protocols (Lee et al., 1990;
Howard et al., 1992). Urine creatinine was measured at the laboratory
of the National Institute of Diabetes and Digestive and Kidney Diseases
Epidemiology and Clinical Research Branch (Phoenix, AZ, USA) using
an automated alkaline picrate methodology run on a rapid flow ana-
lyzer (Lee et al., 1990).
2.5. Statistical methods
We estimated inorganic arsenic exposure (ΣAs) as the sum of urine
iAs, MMA, and DMA. We divided ΣAs by urine creatinine to account for
urine dilution. Because the distribution of ΣAs was right-skewed, we
log-transformed the variable for analysis of both maternal and offspring
ΣAs.
Maternal arsenic values were based on SHS visit 1 (1989–1991).
Offspring arsenic values were based on the baseline SHFS visit
(1998–1999 [n = 147] or 2001–2003 [n = 319]). Fasting glucose and
HOMA2-IR values were obtained from the follow-up SHFS visit
(2006–2009).
We used Spearman correlation coefficients to describe the un-
adjusted association between maternal and offspring arsenic exposure,
as well as between maternal and offspring arsenic exposure and off-
spring fasting glucose and HOMA2-IR.
We used generalized estimation equations (GEE) with an in-
dependent correlation structure to assess the associations of both ma-
ternal ΣAs and offspring ΣAs with offspring fasting glucose levels. A
sensitivity analysis using an exchangeable correlation structure showed
similar results. We estimated the mean difference in offspring glucose
levels per interquartile range (IQR) increase in ΣAs. We also used GEE
to assess the associations of both maternal ΣAs and offspring ΣAs with
offspring log-transformed HOMA2-IR. Here we estimated the geometric
mean ratio (GMR) of HOMA2-IR per IQR increase in ΣAs by multiplying
the beta coefficients by the IQR in log-transformed ΣAs and then ex-
ponentiating the coefficients.
Models were run with progressive adjustments. First, we adjusted
for offspring sex and age at baseline as well as for maternal eGFR for
maternal models or for offspring eGFR for offspring models. Adjustment
for eGFR was included because kidney function impairs the excretion of
ΣAs levels in the urine (Zheng et al., 2015). Second, we further adjusted
offspring and maternal ΣAs models for maternal BMI and maternal
fasting glucose at baseline. This was to ensure that the associations
observed were due to maternal urine arsenic, not to maternal BMI, and
because mothers with increased fasting glucose levels may have dif-
ferent urinary As excretion compared to those with normal fasting
glucose levels. Third, to assess the independent association of maternal
arsenic exposure from adult offspring arsenic exposure, the models for
maternal urine arsenic were adjusted for offspring baseline urine ar-
senic levels (2001–2003 for most SHFS participants), and models for
offspring urine arsenic were adjusted for maternal urine arsenic
(1989–1991). Additionally, a sensitivity analysis controlling for year of
offspring ΣAs measurement was performed to ensure that a possible
decrease in arsenic exposure during this time did not affect the asso-
ciations.
Offspring waist circumference and offspring BMI were added sepa-
rately to the fully adjusted model (model 3), to assess whether the as-
sociation of maternal arsenic exposure with offspring glucose and
HOMA2-IR could be mediated by offspring adiposity. Models with
possible mediator variables were compared to fully adjusted model to
determine whether addition of mediator variables attenuated the as-
sociation. Another sensitivity analysis restricted offspring to
BMI < 25 kg/m2 to further investigate whether the association is
consistent among participants with lower BMI. A third sensitivity ana-
lysis was performed to investigate whether offspring diabetes medica-
tion usage might confound the relationships of offspring ΣAs and ma-
ternal ΣAs with offspring fasting glucose. A four-level variable
indicating whether participants were taking oral diabetes medication,
insulin, both, or neither was added to the fully adjusted model to adjust
for offspring diabetes medication usage. Finally, one further sensitivity
analysis stratified the sample by study center to ensure that the direc-
tions of the associations are consistent across every study site.
Exploratory interaction analyses were additionally performed.
Effect modification by sex and study center was assessed by including
interaction terms to fully adjusted models for both maternal and off-
spring exposure with HOMA2-IR and fasting glucose outcomes. We
additionally assessed the possible interaction between maternal and
offspring ΣAs exposure using two types of models. First, we recoded a 4-
level categorical variable of combined exposure: category 1 was defined
as offspring and maternal ΣAs below the median, category 2 was off-
spring ΣAs below the median but maternal ΣAs above the median, ca-
tegory 3 was offspring ΣAs above the median but maternal ΣAs below
the median, and category 4 was offspring and maternal ΣAs above the
median. Second, we also ran models for maternal and offspring con-
tinuous ΣAs variables including an interaction term for both of them in
the model.
Finally, we conducted exploratory analyses for offspring incident
T2D and incident T2D plus IFG compared with NFG at visit 5. Here we
estimated odds ratio (OR) of T2D or of T2D + IFG per IQR increase in
ΣAs by multiplying the beta coefficients by the IQR and then ex-
ponentiating the coefficients Though the number of SHFS participants
with T2D (79) and with T2D + IFG (182) is relatively small, this
analysis directly explores the relationship between maternal arsenic
exposure and adult T2D status later in life.
All statistical analyses were performed using the R software version
3.5.2. GEE analysis was performed using the ‘geepack’ package.
3. Results
3.1. Participant characteristics
Offspring age ranged from 15 to 69 (median: 41) years old, while
mothers’ age ranged from 45 to 73 (median : 56). Mean (standard de-
viation [SD]) offspring and maternal BMI were 31.6 (7.1) kg/m2 and
31.9 (5.7) kg/m2, respectively. Sixty percent of offspring were female
(Table 1).
Table 1
Median (IQR) values for maternal and offspring age, BMI, ΣAs, estimated glo-
merular filtration rate, waist circumference, and fasting glucose.
Maternal Median (IQR) Offspring Median (IQR)
Age (years) 55.60 (49.62, 62.60) 40.61 (35.81, 46.60)
BMI (kg/m2) 31.64 (27.77, 35.55) 30.48 (26.78, 35.13)
ΣAs (µg/g creatinine) 7.57 (5.13, 12.91) 4.53 (2.98, 7.54)
eGFR (mL/min) 79.30 (69.37, 91.97) 88.96 (77.32, 97.34)
Waist Circ. (cm) 106 (98, 115) 99.00 (91, 112.75)
Fasting Glc (mg/dL) 116 (103, 177) 94.00 (87, 108)
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The median (interquartile range [IQR]) baseline concentrations of
maternal and offspring ΣAs were 7.57 (5.13, 12.91) and 4.53 (2.98,
7.54) µg/g creatinine, respectively (Table 1). Total urinary arsenic
concentrations were highest among mothers from Arizona (median
21.8 µg/g creatinine), followed by mothers from North and South Da-
kota (9.2 µg/g creatinine) and Oklahoma (6.2 µg/g creatinine) (Fig. 1).
This is expected, as groundwater in Arizona has higher arsenic con-
centrations than the other states in the SHS (Navas-Acien et al., 2009).
The analyses stratified by center showed that the associations remained
consistent across centers, with somewhat stronger associations in
North/South Dakota, the region with higher within region variability in
arsenic exposure. (Supplemental Table 3).
Maternal ΣAs and offspring ΣAs were significantly correlated
(r = 0.48, p-value < 0.001) (Fig. 2). At study visit 5, the median (IQR)
offspring glucose and HOMA2-IR were 94 (87–108) µg/dL and 1.38
(0.78–2.22), respectively.
3.2. Association of maternal and offspring ΣAs with offspring fasting
glucose
Maternal ΣAs and offspring ΣAs were significantly correlated with
offspring fasting glucose (r = 0.19, p-value < 0.001, and r = 0.12
respectively, p-value = 0.008) (Fig. 2). After adjustment for offspring
sex and age, and for maternal eGFR, the mean difference (95% CI) in
offspring glucose was 7.83 (0.01, 15.65) mg/dL for an interquartile
range (IQR) increase in maternal ΣAs (Table 2). While adjustment for
maternal BMI and maternal fasting glucose had a minor impact (mean
difference (95% CI) 6.79 (−0.70, 14.28) mg/dL), further adjustment
for offspring ΣAs attenuated the effect estimate to 4.40 (−3.46, 12.26)
mg/dL. Mean differences for the relationship between adult offspring
ΣAs and fasting glucose followed a similar trend, with a minimally and
fully adjusted mean difference (95% CI) of 5.40 (−1.75, 12.55) mg/dL
and 2.72 (−4.91, 10.34) mg/dL respectively (Table 2).
In the maternal ΣAs and offspring glucose models, the addition of
offspring BMI and waist circumference attenuated the mean difference
(95% CI) to 2.12 (−4.36, 8.59) mg/dL and 1.68 (−4.82, 8.18) mg/dL
for an IQR increase in maternal ΣAs respectively. In the offspring ΣAs
and glucose models, the addition of BMI and waist circumference
strengthened the association to a mean difference (95% CI) of 4.88
(−2.07, 11.84) mg/dL and 4.25 (−2.68, 11.18) mg/dL (Table 2).
When restricting to individuals with BMI < 25 k/m2, the mean
difference in fasting glucose levels was larger in offspring models than
in maternal models, though none were statistically significant
(Supplemental Table 3). The addition of offspring diabetes medication
usage attenuated the mean difference (95% CI) in fasting glucose levels
to 3.89 (−2.43, 10.20) mg/dL in maternal models, and 1.79 (−4.48,
8.06) mg/dL in offspring models (Supplemental Table 3).
3.3. Association of maternal and offspring ΣAs with offspring HOMA2-IR
Neither maternal ΣAs nor offspring ΣAs were correlated with off-
spring HOMA2-IR (Fig. 2). In linear regression models, after adjusting
for offspring sex and age and maternal eGFR, the GMR (95% CI) of
offspring HOMA2-IR was 1.04 (0.92, 1.17) for an IQR increase in ma-
ternal ΣAs, and it was 0.93 (0.84, 1.03) for an IQR increase in offspring
ΣAs (Table 2). The fully adjusted model was largely unchanged for
maternal ΣAs (GMR (95% CI): 1.04 (0.93, 1.16)), and was slightly
strengthened for offspring ΣAs (GMR (95% CI): 0.89 (0.80, 0.99))
(Table 2).
For maternal ΣAs, the addition of offspring BMI and waist cir-
cumference attenuated the GMR (95% CI) to 1.02 (0.93, 1.13) and 1.01
(0.93, 1.11) for an IQR increase in maternal ΣAs respectively. Similarly,
for offspring ΣAs, the addition of BMI and waist circumference atte-
nuated the association to a GMR (95% CI) of 0.96 (0.87, 1.07) and 0.95
(0.86, 1.04) (Table 2).
When restricting to individuals with BMI < 25 kg/m2, the GMR for
HOMA2-IR was larger in offspring models than in maternal models,
with maternal ΣAs exposure showing an inverse association (GMR (95%
CI): 0.75 (0.59, 0.95) (Supplemental Table 3).
We observed consistent results in the sensitivity analysis adjusting
for year of offspring ΣAs measurement (data not shown).
3.4. Effect modification analysis
Compared to participants with low maternal and low offspring ΣAs
levels, the mean difference in fasting plasma glucose was 8.16 (95% CI:
−4.12, 20.44) mg/dL for those with both high maternal and offspring
ΣAs, 2.16 (95% CI: −9.04, 13.36) mg/dL for those with high maternal
but low offspring ΣAs, and −1.23 (95% CI: −11.88, 9.43) mg/dL for
those with low maternal but high offspring ΣAs (Supplemental Table 1).
Compared to participants with low maternal and low offspring ΣAs
levels, the GMR for HOMA2-IR was 0.83 (95% CI: 0.55, 1.25) for those
with both high maternal and offspring ΣAs, 1.04 (95% CI: 0.56, 1.92)
for those with high maternal but low offspring ΣAs, and 0.81 (95% CI:
0.54, 1.21) for those with low maternal but high offspring ΣAs
(Supplemental Table 1).
The coefficient (95% CI) for the interaction between continuous
maternal and offspring ΣAs on fasting glucose was 0.05 (−0.01, 0.12)
Fig. 1. Median and interquartile range (IQR) for maternal and offspring total
arsenic by offspring characteristics. Age, smoking status, and BMI were mea-
sured at baseline, while fasting glucose and HOMA2-IR are from SHFS visit 5.
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(p-value = 0.12), and on HOMA2-IR was −0.22 (−0.63, 0.19) (p-
value = 0.53). Interaction by sex and study center was assessed in an
exploratory manner (and limited due to the small sample size) with no
significant interaction detected, although power for interactions might
be limited due to small sample sizes, especially in Arizona.
3.5. Incident diabetes
In fully adjusted logistic regression models, the OR (95% CI) of
incident offspring T2D was 1.35 (1.07, 1.69) for an IQR increase in
maternal ΣAs, and it was 1.15 (0.92, 1.43) for an IQR increase in off-
spring ΣAs. The fully adjusted OR (95% CI) of incident offspring
T2D + IFG was 1.42 (1.18, 1.72) for an IQR increase in maternal ΣAs,
Fig. 2. Spearman correlation matrix for maternal total arsenic, offspring total arsenic, offspring glucose, and offspring HOMA2-IR.
Table 2
Mean difference (95% CI) in offspring glucose for IQR increase in total ΣAs, and geometric mean ratio (95% CI) of offspring HOMA-IR by ΣAs.
Glucose (n = 466) HOMA2-IR (n = 387)
Maternal ΣAs Offspring ΣAs Maternal ΣAs Offspring ΣAs
Model 1 7.83 (0.01, 15.65) 5.40 (−1.75, 12.55) 1.04 (0.92, 1.17) 0.93 (0.84, 1.03)
Model 2 6.79 (−0.70, 14.28) 4.73 (−2.30, 11.75) 1.00 (0.90, 1.11) 0.90 (0.81, 1.00)
Model 3 4.40 (−3.46, 12.26) 2.72 (−4.91, 10.34) 1.04 (0.93, 1.16) 0.89 (0.80, 0.99)
Model 4 2.12 (−4.36, 8.59) 4.88 (−2.07, 11.84) 1.02 (0.93, 1.13) 0.96 (0.87, 1.07)
Model 5 1.68 (−4.82, 8.18) 4.25 (−2.68, 11.18) 1.01 (0.93, 1.11) 0.95 (0.86, 1.04)
Model 1 is adjusted for offspring sex and age at baseline visit, and maternal eGFR at baseline for maternal models or offspring eGFR for offspring models.
Model 2 = Model 1 + maternal BMI (kg/m2) and maternal fasting glucose (mg/dL) at baseline.
Model 3 = Model 2 + offspring ΣAs in maternal models or maternal ΣAs in offspring models (fully adjusted model).
Model 4 = Model 3 + offspring BMI at baseline.
Model 5 = Model 3 + offspring waist circumference at baseline.
Geometric mean ratios (95% CI) are reported per an increase equal to the IQR in ΣAs distribution.
Generalized estimation equations (GEE) used to account for family clustering.
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and it was 1.03 (0.85, 1.24) for an IQR increase in offspring ΣAs
(Table 3)
The addition of offspring BMI and offspring waist circumference
supported partial mediation by both variables in maternal ΣAs models,
which is consistent with results from glucose analyses. In offspring
models, the association increased with the addition of offspring BMI
and waist circumference, which was also consistent with other analyses
(Table 3).
4. Discussion
In this population of American Indians from Oklahoma, Arizona,
and North and South Dakota, maternal ΣAs was prospectively asso-
ciated with offspring fasting glucose and incident diabetes. Results were
consistent after adjustment for offspring age and sex, and maternal
eGFR, as well as, although no longer significant for fasting glucose, after
adjustment for maternal BMI and maternal glucose. Higher offspring
ΣAs was non-significantly associated with higher offspring glucose and
incident T2D. Maternal ΣAs was positively but non-significantly asso-
ciated with HOMA-IR, while offspring ΣAs was inversely and sig-
nificantly associated with HOMA-IR. Both for plasma glucose and in-
cident T2D, the magnitude of the association was markedly attenuated
with adjustment for offspring BMI –and especially for waist cir-
cumference– suggesting possible mediation by central adiposity.
Although limited by a small sample size and limited statistical power,
these findings support the DOHaD hypothesis that in-utero exposures
can lead to adverse health outcomes later in life.
Urinary arsenic levels were lower in the offspring (median ΣAs
4.53 µg/g creatinine) compared to the maternal (7.57 µg/g creatinine).
These reductions in exposure are positive for the population, however,
results from this study support that maternal arsenic exposure may
affect risk for adult T2D outcomes. The mechanism behind these asso-
ciations are unknown, but it is hypothesized that arsenic-induced epi-
genetic DNA modifications passed down from mother to offspring could
influence offspring T2D-related outcomes (Kile et al., 2014; Kushal
et al., 2017).
Recent research has shown that various mechanisms could explain
the relationship between As exposure and genetic imprinting. Arsenic
exposure can both increase and decrease promotor region methylation
in various genes, resulting in either downregulation or upregulation of
those genes, and thus various health effects. These epigenetic changes
have the potential to be passed down across generations (Smeester
et al., 2014). Epigenetic changes in several genes have been associated
with both As exposure and increased T2D risk through various path-
ways. Differential methylation of genes involved in regulation of insulin
production (PDX1, INS) and secretion (VAMP2) has been associated
with As exposure (Martin et al., 2017). Future research should
investigate these associations further, as well as explore other potential
imprinted genes related to As exposure and T2D development.
One potential mechanism for the relationship between maternal ΣAs
exposure and adult offspring T2D-related outcomes is through low birth
weight. Numerous studies have shown that maternal arsenic exposure is
related to low birth weight (Hopenhayn et al., 2003; Huyck et al.,
2007), some suggesting that a molecular mechanism for this involves
both increase and decreased gene expression. One study in particular
showed that in utero As exposure was associated with increased ex-
pression of the gene AQP9, which increases cellular As uptake. In-
creased expression of AQP9 is followed by decreased expression of the
gene ENPP2, which is associated with decreased infant birth weight (Fei
et al., 2013). Other potential mechanisms exist, and confirmation of
these genetic biomarkers will require further research.
Both low and high birth weight have been widely associated with
development of T2D later in life, though the mechanisms of this asso-
ciation are debated (Harder et al., 2007). Potential mechanisms involve
impaired programming of neuroendocrine circuits in infants. One
widely supported hypothesis is that low birthweight babies are sub-
jected to overfeeding, resulting in both rapid weight gain, which is
associated with overweight and obesity later in life, and impaired
programming of circuits regulating appetite control, body weight, and
metabolism (Plagemann et al., 1999). High birthweight babies are also
likely subject to this impaired programming, but due to exposure to
maternal hyperglycemia in utero (Silverman et al., 1991). In our study,
unfortunately data on birth weight was not available. In analyses re-
stricted to participants with BMI < 25 kg/m2, the association of ma-
ternal As exposure with fasting glucose was weaker compared to the
overall association, supporting that the association between maternal
arsenic exposure and offspring glucose could be mediated by an impact
of maternal arsenic on offspring BMI.
Additional research should assess the possible mediation of low
birth weight and offspring weight gain on the relationship between
maternal arsenic exposure and adult T2D and related outcomes.
In this study, we observed opposite effects for maternal As and
offspring As on insulin resistance. The results for maternal As, but not
for offspring As, are consistent with a higher risk for insulin resistance,
a major underlying mechanism for T2D. The inverse association be-
tween adult arsenic exposure and HOMA2-IR was also found in studies
in Mexico (Del Razo et al., 2011), and could potentially be related to As
affecting pancreatic function.
To our knowledge, this study is the first to prospectively evaluate
the association between maternal arsenic exposure and adult T2D-re-
lated outcomes. Previous studies have shown significant effects of
maternal arsenic exposure during pregnancy on decreased birth weight
(Rahman et al., 2009), increased risk of infection in infants, higher
infant mortality (Farzan et al., 2013), and increased occurrence of lung
Table 3
Odds ratios (95% CI) of incident diabetes or diabetes + IFG at visit 5 by urinary ΣAs at baseline.
Diabetes (79/387) Diabetes and IFG (182/284)
(n = 466) Maternal ΣAs Offspring ΣAs Maternal ΣAs Offspring ΣAs
Model 1 1.43 (1.16, 1.78) 1.27 (1.03, 1.58) 1.45 (1.15, 1.83) 1.18 (0.99, 1.40)
Model 2 1.43 (1.15, 1.78) 1.26 (1.01, 1.56) 1.42 (1.18 1.71) 1.15 (0.96, 1.38)
Model 3 1.35 (1.07, 1.69) 1.15 (0.92, 1.43) 1.42 (1.18 1.72) 1.03 (0.85, 1.24)
Model 4 1.20 (0.95, 1.53) 1.26 (1.00, 1.58) 1.32 (1.09 1.59) 1.12 (0.91, 1.37)
Model 5 1.18 (0.94, 1.49) 1.23 (0.98, 1.54) 1.30 (1.08 1.56) 1.09 (0.88, 1.35)
Model 1 is adjusted for offspring sex and age at baseline visit, and maternal eGFR at baseline for maternal models or offspring eGFR for offspring models.
Model 2 = Model 1 + maternal BMI (kg/m2) and maternal fasting glucose (mg/dL) at baseline.
Model 3 = Model 2 + offspring ΣAs in maternal models or maternal ΣAs in offspring models (fully adjusted model).
Model 4 = Model 3 + offspring BMI at baseline.
Model 5 = Model 3 + offspring waist circumference at baseline.
Odds ratios (95% CI) are reported per an increase equal to the IQR in ∑As distribution.
Numbers in brackets are cases and non-cases.
GEE used to account for family clustering.
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disease, cardiovascular disease, and cancer in childhood and later in life
(Dauphiné et al., 2011; Yuan et al., 2007; Liaw et al., 2009). Our
findings provide evidence that maternal arsenic exposure may also play
a role in risk for adult-onset T2D. Further, our results suggest that
offspring BMI and waist circumference may partially mediate the as-
sociations of maternal ΣAs with offspring fasting glucose and insulin
resistance, as well as offspring ΣAs with insulin resistance.
Strengths of this study include the standardized protocol, high
quality of laboratory methods, and length of follow-up time to allow for
analysis of outcomes in adult offspring. However, there are also several
limitations. First, there is a slight possibility of collinearity between
maternal ΣAs and offspring ΣAs, as both exposures are significantly
correlated. Their correlation, however, is moderate (r = 0.48).
Additionally, maternal exposure was estimated from a single maternal
urine sample. Although studies have shown urine ΣAs to be relatively
stable over time (Navas-Acien et al., 2009), we were unable to measure
maternal arsenic during pregnancy as the participants in the SHS ori-
ginal cohort were recruited when they were 45 years and older. For this
reason, we were unable to investigate the role of arsenic exposure oc-
curring during pregnancy. In a sensitivity analysis adjusting for T2D
medication, the associations remained, although attenuated, after ad-
justment. Finally, other potential confounders include diet and genetics.
However, dietary sources of arsenic in the population have shown to
explain< 4% of urinary As levels, supporting water as the main source
of arsenic in SHS communities (Nigra et al., 2019).
In conclusion, maternal arsenic exposure was non-significantly as-
sociated with adult offspring fasting glucose levels among a small
sample of men and women from American Indian communities in
Arizona, Oklahoma, and North and South Dakota. The association was
independent of offspring adult arsenic exposure and somewhat stronger
for maternal exposure, although the associations were not significant.
These non-significant associations were also attenuated after adjust-
ment for offspring BMI and waist circumferences, suggesting potential
mediation by central adiposity. Further research is necessary to confirm
these findings and to better understand the biological mechanisms be-
hind the observed associations, including the possible role of long-term
epigenetic effects of early life arsenic exposure.
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